Benzinga''s Top Ratings Upgrades, Downgrades For April 5, 2022
Upgrades Wolfe Research upgraded the previous rating for Landstar System Inc (NASDAQ: LSTR ) from Underperform to Peer Perform. In the fourth quarter, Landstar System showed an EPS of $2.99, compared to $2.01 from the year-ago quarter. The current stock performance of Landstar System shows a 52-week-high of $188.62 and a 52-week-low of $139.12. Moreover, at the end of the last trading period, the closing price was at $142.64. According to Wolfe Research, the prior rating for Expeditors International of Washington Inc (NASDAQ: EXPD ) was changed from Underperform to Peer Perform. In the fourth quarter, Expeditors International showed an EPS of $2.66, compared to $1.16 from the year-ago quarter. At the moment, the stock has a 52-week-high of $137.80 and a 52-week-low of $97.37. Expeditors International closed at $100.46 at the end of the last trading period. Barclays upgraded the previous rating for Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) from Equal-Weight to Overweight. Teva Pharmaceutical Indus earned $0.77 in the fourth quarter, compared to $0.68 in the year-ago quarter.
Benzinga''s Top Ratings Upgrades, Downgrades For April 5, 2022
Upgrades Wolfe Research upgraded the previous rating for Landstar System Inc (NASDAQ: LSTR ) from Underperform to Peer Perform. In the fourth quarter, Landstar System showed an EPS of $2.99, compared to $2.01 from the year-ago quarter. The current stock performance of Landstar System shows a 52-week-high of $188.62 and a 52-week-low of $139.12. Moreover, at the end of the last trading period, the closing price was at $142.64. According to Wolfe Research, the prior rating for Expeditors International of Washington Inc (NASDAQ: EXPD ) was changed from Underperform to Peer Perform. In the fourth quarter, Expeditors International showed an EPS of $2.66, compared to $1.16 from the year-ago quarter. At the moment, the stock has a 52-week-high of $137.80 and a 52-week-low of $97.37. Expeditors International closed at $100.46 at the end of the last trading period. Barclays upgraded the previous rating for Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) from Equal-Weight to Overweight. Teva Pharmaceutical Indus earned $0.77 in the fourth quarter, compared to $0.68 in the year-ago quarter.